Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Merck Ad5 HIV-1 Vaccine Dose-Refinement Study
NCT00350623Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Primary completion
- May 2008
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
A Phase 2 trial of trivalent MRKAd5 HIV-1 gag/pol/nef vaccine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Oct 2006; status: terminated.
02
Drugs
trivalent MRKAd5 HIV-1 gag/pol/nef vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00350623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350623.